XLS — Xlife Sciences AG Income Statement
0.000.00%
- CH₣112.83m
- CH₣263.31m
- CH₣0.83m
- 39
- 57
- 29
- 33
Annual income statement for Xlife Sciences AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.397 | 0.806 | 1.03 | 0.988 | 0.835 |
Cost of Revenue | |||||
Gross Profit | -0.026 | 0.359 | 0.186 | 0.449 | 0.55 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.49 | 6.04 | 22 | 21.3 | 20.2 |
Operating Profit | -3.09 | -5.23 | -21 | -20.3 | -19.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 21.2 | 53.2 | 4.04 | 4.53 | 24 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21.1 | 53.3 | 8.78 | 9.27 | 28.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 21.5 | 53.4 | 14.3 | 14.9 | 34.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 21.5 | 53.4 | 14.3 | 14.9 | 34.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 3.6 | 8.66 | 1.97 | 2.08 | 4.67 |
Dividends per Share |